Thymidylate Synthase (5-FU Resistance Marker) Antibody - Without BSA
Mouse Monoclonal Antibody [Clone TMS715 ]
|Application ||IHC-P, IF, FC|
|Other Accession||7298, 369762|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Thymidylate synthase, TS, TSase, 184.108.40.206, TYMS, TS|
|Format||200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA at 1.0mg/ml.|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Thymidylate Synthase (5-FU Resistance Marker) Antibody - Without BSA is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.|
|Cellular Location||Nucleus. Cytoplasm. Mitochondrion. Mitochondrion matrix. Mitochondrion inner membrane|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
It recognizes a protein of 36kDa, identified as Thymidylate Synthase (TS) (EC 220.127.116.11). TS converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis. TS is also a critical target for the fluoropyrimidines, an important group of antineoplastic drugs that are widely used in the treatment of solid tumors. Both 5-FU and fluorodeoxyuridine are converted in tumor cells to FdUMP which inactivates TS by formation of a ternary covalent complex in the presence of the folate cofactor 5,10-methylenetetrahydrofolate. Expression of TS protein is associated with response to 5-fluorouracil (5-FU) in human colorectal, gastric, head and neck, and breast carcinomas.
Johnston PG, et. al. Journal of the National Cancer Institute, 1997, 89(4):308-13. | Pestalozzi BC, et. al. Journal of Clinical Oncology, 1997, 15(5):1923-31
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.